Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

SaaS Business Update

7 Mar 2018 07:00

RNS Number : 9062G
Instem plc
07 March 2018
 

7 March 2018

Instem plc

 

("Instem" or the "Company")

 

SaaS Business Update

 

Growing demand for Instem's Software-as-a-Service ("SaaS") delivery model

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that one of the world's largest chemical products companies is the latest customer to adopt the Company's market leading SaaS delivery model for accessing its solutions via the Instem Cloud. Annual recurring revenue from this client will immediately increase by over 40%.

 

The growing shift towards the SaaS based revenue model will see a continued improvement of earnings visibility for Instem and will ultimately deliver an expansion in operating margins in-line with similar cloud-based delivery models.

 

Originally developed to attract new clients, this latest client to adopt the Company's SaaS approach has been using Instem's Provantis® software for more than 12 years and represents the growing trend to move from on-site installations to the Company's highly secure, cloud-based SaaS offering.

 

 

Instem's SaaS Platform

Instem's SaaS clients enjoy a reduced IT burden, flexibility and scalability to meet their changing needs, giving them faster access to new product releases and high quality shared services that in turn deliver an enhanced customer experience in terms of lower total cost of ownership, rapid implementation and high reliability.

 

Instem's professionally managed online platforms are run from centralised state-of-the-art third-party data centres, which can be accessed from any location that offers connectivity to the Internet, 24 hours a day, seven days a week, and are currently being used every day by drug developers, contract research organisations, universities, research institutes and government agencies around the world.

 

 

SaaS Impact on Quality of Earnings

The 40% increase in recurring revenue from one client is typical of Instem clients converting from on premise to SaaS deployment. With £3.4m of existing SaaS revenue and £9.6m of non-SaaS based recurring revenue, procured on an annual basis, reported for the 12 months to 30 June 2017, there remains a significant opportunity to achieve material increases in SaaS based revenue recognition over the next few years as clients make the transition.

 

ISO 27001

With an ever-increasing volume of high-value client data under its control, Instem has been independently certified to the international standard for information security management systems, ISO 27001. This is another unique differentiator for Instem in a market environment that has become highly focused on information security. The newly awarded certification to ISO 27001 is also a significant component in ensuring both internal and client compliance with EU General Data Protection Regulation ('GDPR') which becomes law on 25 May 2018, which we believe is another reason why customers are switching to Instem's SaaS cloud delivery platform.

 

Phil Reason, CEO of Instem plc, commented: "The strategic process of migrating clients from on-site installations to our market leading SaaS model continues apace. This latest agreement with a leading chemical client sees Instem deploy its Provantis® product from its own secure cloud services environment, as opposed to the client's own data centre, thereby reducing their cost of ownership while improving Instem's software deployment and management efficiencies."

 

"The transition to SaaS across the regulatory life sciences industry has been quickening in recent months after initial concerns over data security and the generally conservative nature of the participants. However, both existing clients and new prospects are now fully recognising Instem's leadership in this area and with GDPR coming into effect in May of this year we anticipate strong growth in SaaS revenue."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

Rachel Hayes

Walbrook Financial PR

+44 (0) 20 7933 8000

Paul Cornelius

instem@walbrookpr.com

Sam Allen

Helen Cresswell

 

About Instem

 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

 

About Provantis®

Provantis® is a modern, fully integrated Windows-based system for organisations engaged in non-clinical evaluation studies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDJFMBTMBMMTMP
Date   Source Headline
18th May 20071:09 pmRNSRule 8.3- Intnl Nuclear Sol.
17th May 20075:02 pmRNSRule 8.3- Int Nuclear Sol
17th May 20073:25 pmBUSRule 8.3 - International Nuclear Solutions
16th May 20079:13 amRNSNotification of shares
14th May 200710:40 amRNSEGM ADJOURNMENT
11th May 200711:48 amRNSHolding(s) in Company
11th May 20079:42 amRNSHolding(s) in Company
10th May 20073:04 pmBUSRule 8.3 - International Nuclear Solution
10th May 20071:44 pmRNSRule 8.3-Int'l Nuclear Sol
1st May 200711:44 amRNSHolding(s) in Company
1st May 200710:00 amRNSRule 8.3- Intnl Nuclear Sols
30th Apr 20074:26 pmRNSHolding(s) in Company
26th Apr 20073:29 pmBUSRule 8.3 - International Nuclear Solutions
26th Apr 20073:07 pmRNSRule 8.3-Intl Nuclear Sol
26th Apr 20072:28 pmRNSRule 8.3- Intl Molybdenum plc
25th Apr 20073:17 pmBUSRule 8.3 - International Nuclear Solutions
25th Apr 200712:41 pmRNSRule 8.3- Int'l Nuclear Sol
23rd Apr 20071:34 pmRNSRule 8.3-Int. Nuclear
20th Apr 20074:30 pmRNSPosting of Scheme Document
18th Apr 20073:32 pmBUSRule 8.3 - International Nuclear Solutions
18th Apr 200710:09 amRNSRule 8.3- Intnl Nuclear Sol.
12th Apr 20073:05 pmBUSRule 8.3 - International Nuclear Solutions
5th Apr 20075:02 pmBUSRule 8.3 - International Nuclear Solution
5th Apr 200711:39 amRNSRule 8.3- Intnl Nuclear Sol.
5th Apr 200711:00 amRNSRule 8.3- Intnl Nuclear Sol
4th Apr 20074:21 pmRNSRule 8.3- Int Nuclear Sol
4th Apr 20073:30 pmBUSRule 8.3 - International Nuclear Solutions
4th Apr 200711:47 amRNSRule 8.3- Intnl Nuclear Sol.
4th Apr 20077:02 amRNSRecommended Cash Offer
4th Apr 20077:02 amRNSScheme of arrangement
3rd Apr 20075:29 pmRNSCorrection to Prelims
30th Mar 20073:13 pmBUSRule 8.3 - International Nuclear Solutions
29th Mar 20073:21 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
28th Mar 20073:27 pmRNSRule 8.3-Int Nuclear Sol
27th Mar 20077:02 amRNSFinal Results
26th Mar 200711:37 amRNSRule 8.3- Intnl Nuclear Sol.
23rd Mar 20073:26 pmBUSRule 8.3 - International Nuclear Solutions
19th Mar 200711:06 amRNSRule 8.3- Intnl Nuclear Sol.
8th Mar 200711:59 amRNSRule 8.3- Intnl Nuclear Sol.
20th Feb 20072:34 pmBUSRule 8.3 - Internationa Nuclear Solutions
16th Feb 200710:50 amRNSRule 8.3- Intnl Nuclear Sol.
12th Feb 200712:06 pmRNSRule 8.3- Intnl Nuclear Sol.
7th Feb 20073:18 pmBUSRule 8.3 - International Nuclear Solutions
1st Feb 200710:40 amRNSRule 8.3- Intnl Nuclear Sol.
30th Jan 200711:01 amRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20072:39 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20071:51 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 200711:00 amRNSRule 8.3- Intnl Nuclear
26th Jan 20075:45 pmRNSShare Interest
26th Jan 20073:20 pmRNSRule 8.1- Int Nuclear Sols

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.